46.68 USD
+0.45 (+0.97%)
46.68 USD
0 (0%)
COLL gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. COLL has an excellent profitability rating, but there are some minor concerns on its financial health. COLL may be a bit undervalued, certainly considering the very reasonable score on growth With these ratings, COLL could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
COLL had positive earnings in the past year.
COLL had a positive operating cash flow in the past year.
Of the past 5 years COLL 4 years were profitable.
Each year in the past 5 years COLL had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 3.64%, COLL belongs to the best of the industry, outperforming 84.38% of the companies in the same industry.
Looking at the Return On Equity, with a value of 21.27%, COLL belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 9.10%, COLL belongs to the top of the industry, outperforming 88.02% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for COLL is in line with the industry average of 12.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROIC | 9.1% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
1.3 Margins
COLL has a better Profit Margin (7.72%) than 83.33% of its industry peers.
COLL's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 20.74%, COLL belongs to the top of the industry, outperforming 88.02% of the companies in the same industry.
COLL's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 57.22%, COLL is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
In the last couple of years the Gross Margin of COLL has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% |
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
2. Health
2.1 Basic Checks
COLL has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for COLL has been reduced compared to 1 year ago.
Compared to 5 years ago, COLL has less shares outstanding
The debt/assets ratio for COLL has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.47, we must say that COLL is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.47, COLL is in line with its industry, outperforming 58.33% of the companies in the same industry.
COLL has a debt to FCF ratio of 2.79. This is a good value and a sign of high solvency as COLL would need 2.79 years to pay back of all of its debts.
COLL has a Debt to FCF ratio of 2.79. This is amongst the best in the industry. COLL outperforms 90.63% of its industry peers.
COLL has a Debt/Equity ratio of 2.71. This is a high value indicating a heavy dependency on external financing.
COLL has a worse Debt to Equity ratio (2.71) than 80.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Altman-Z | 1.47 |
ROIC/WACC1.03
WACC8.83%
2.3 Liquidity
A Current Ratio of 1.36 indicates that COLL should not have too much problems paying its short term obligations.
With a Current ratio value of 1.36, COLL is not doing good in the industry: 73.44% of the companies in the same industry are doing better.
COLL has a Quick Ratio of 1.27. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
COLL has a worse Quick ratio (1.27) than 70.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 30.73% over the past year.
COLL shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 154.78% yearly.
The Revenue has grown by 26.34% in the past year. This is a very strong growth!
The Revenue has been growing by 16.31% on average over the past years. This is quite good.
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
3.2 Future
The Earnings Per Share is expected to decrease by -1.58% on average over the next years.
COLL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.62% yearly.
EPS Next Y40.67%
EPS Next 2Y14.84%
EPS Next 3Y5.61%
EPS Next 5Y-1.58%
Revenue Next Year19.45%
Revenue Next 2Y11.07%
Revenue Next 3Y4.6%
Revenue Next 5Y3.62%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 6.49, the valuation of COLL can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 94.79% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.15, COLL is valued rather cheaply.
COLL is valuated cheaply with a Price/Forward Earnings ratio of 5.49.
COLL's Price/Forward Earnings ratio is rather cheap when compared to the industry. COLL is cheaper than 95.83% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of COLL to the average of the S&P500 Index (36.12), we can say COLL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.49 | ||
| Fwd PE | 5.49 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, COLL is valued cheaply inside the industry as 97.92% of the companies are valued more expensively.
95.31% of the companies in the same industry are more expensive than COLL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.1 | ||
| EV/EBITDA | 4.82 |
4.3 Compensation for Growth
COLL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of COLL may justify a higher PE ratio.
PEG (NY)0.16
PEG (5Y)N/A
EPS Next 2Y14.84%
EPS Next 3Y5.61%
5. Dividend
5.1 Amount
No dividends for COLL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
46.68
+0.45 (+0.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners116.73%
Inst Owner Change0.64%
Ins Owners1.56%
Ins Owner Change-0.63%
Market Cap1.48B
Revenue(TTM)757.07M
Net Income(TTM)58.44M
Analysts81.82
Price Target47.74 (2.27%)
Short Float %17.38%
Short Ratio12.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.9%
Min EPS beat(2)1.88%
Max EPS beat(2)7.92%
EPS beat(4)4
Avg EPS beat(4)6.15%
Min EPS beat(4)1.88%
Max EPS beat(4)12.85%
EPS beat(8)7
Avg EPS beat(8)12.99%
EPS beat(12)9
Avg EPS beat(12)-15.06%
EPS beat(16)10
Avg EPS beat(16)-21.97%
Revenue beat(2)2
Avg Revenue beat(2)5.22%
Min Revenue beat(2)1.9%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)2.75%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)8.53%
Revenue beat(8)4
Avg Revenue beat(8)0.8%
Revenue beat(12)6
Avg Revenue beat(12)0.28%
Revenue beat(16)8
Avg Revenue beat(16)-3.75%
PT rev (1m)4.93%
PT rev (3m)5.88%
EPS NQ rev (1m)7.86%
EPS NQ rev (3m)8.88%
EPS NY rev (1m)0%
EPS NY rev (3m)29.1%
Revenue NQ rev (1m)5.8%
Revenue NQ rev (3m)4%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)0.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.49 | ||
| Fwd PE | 5.49 | ||
| P/S | 1.95 | ||
| P/FCF | 5.1 | ||
| P/OCF | 5.07 | ||
| P/B | 5.37 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.82 |
EPS(TTM)7.19
EY15.4%
EPS(NY)8.51
Fwd EY18.22%
FCF(TTM)9.15
FCFY19.61%
OCF(TTM)9.2
OCFY19.72%
SpS23.95
BVpS8.69
TBVpS-18.86
PEG (NY)0.16
PEG (5Y)N/A
Graham Number37.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROCE | 13.6% | ||
| ROIC | 9.1% | ||
| ROICexc | 12.09% | ||
| ROICexgc | N/A | ||
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% | ||
| FCFM | 38.21% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
ROICexc(3y)16.99%
ROICexc(5y)14.94%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)16.56%
ROCE(5y)13.94%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y15.58%
ROICexc growth 5YN/A
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Debt/EBITDA | 1.94 | ||
| Cap/Depr | 0.72% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 2.17 | ||
| Cash Conversion | 75.92% | ||
| Profit Quality | 495.01% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 | ||
| Altman-Z | 1.47 |
F-Score7
WACC8.83%
ROIC/WACC1.03
Cap/Depr(3y)142.93%
Cap/Depr(5y)207.67%
Cap/Sales(3y)41.34%
Cap/Sales(5y)49.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
EPS Next Y40.67%
EPS Next 2Y14.84%
EPS Next 3Y5.61%
EPS Next 5Y-1.58%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
Revenue Next Year19.45%
Revenue Next 2Y11.07%
Revenue Next 3Y4.6%
Revenue Next 5Y3.62%
EBIT growth 1Y-18.86%
EBIT growth 3Y89.16%
EBIT growth 5YN/A
EBIT Next Year149%
EBIT Next 3Y27.45%
EBIT Next 5Y18.85%
FCF growth 1Y8.55%
FCF growth 3Y25.98%
FCF growth 5Y56.88%
OCF growth 1Y8.67%
OCF growth 3Y25.54%
OCF growth 5Y49.12%
COLLEGIUM PHARMACEUTICAL INC / COLL FAQ
What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?
ChartMill assigns a fundamental rating of 6 / 10 to COLL.
Can you provide the valuation status for COLLEGIUM PHARMACEUTICAL INC?
ChartMill assigns a valuation rating of 9 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.
What is the profitability of COLL stock?
COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 8 / 10.
Can you provide the financial health for COLL stock?
The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 5 / 10.